BridgeBio Oncology Therapeutics, Inc.
BBOT
$11.30
$0.232.03%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 09/30/2024 | ||
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 468.29M | 131.40M | 135.72M | -- | |
| Total Receivables | 226.00K | 1.08M | 40.00K | -- | |
| Inventory | -- | -- | -- | -- | |
| Prepaid Expenses | 7.50M | 4.30M | 2.67M | -- | |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | |
| Other Current Assets | -- | 5.58M | 2.90M | -- | |
| Total Current Assets | 476.01M | 142.35M | 141.33M | -- | |
|
|
|||||
| Total Current Assets | 476.01M | 142.35M | 141.33M | -- | |
| Net Property, Plant & Equipment | 3.27M | 3.45M | 3.36M | -- | |
| Long-term Investments | -- | -- | -- | -- | |
| Goodwill | -- | -- | -- | -- | |
| Total Other Intangibles | -- | -- | -- | -- | |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | |
| Total Other Assets | 5.52M | 5.46M | 5.15M | -- | |
| Total Assets | 484.79M | 151.25M | 149.84M | -- | |
|
|
|||||
| Total Accounts Payable | 3.65M | 2.20M | 3.65M | -- | |
| Total Accrued Expenses | 30.87M | 24.40M | 16.08M | -- | |
| Short-term Debt | -- | -- | -- | -- | |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | |
| Finance Division Debt Current | 506.00K | 320.00K | 6.00K | -- | |
| Total Finance Division Other Current Liabilities | 691.00K | 330.00K | 4.32M | -- | |
| Total Other Current Liabilities | 691.00K | 330.00K | 4.32M | -- | |
| Total Current Liabilities | 35.71M | 27.25M | 24.06M | -- | |
|
|
|||||
| Total Current Liabilities | 35.71M | 27.25M | 24.06M | -- | |
| Long-Term Debt | -- | -- | -- | -- | |
| Short-term Debt | -- | -- | -- | -- | |
| Capital Leases | 2.38M | 2.51M | 2.64M | -- | |
| Finance Division Debt Non Current | -- | -- | -- | -- | |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | |
| Total Other Liabilities | -- | -- | -- | -- | |
| Total Liabilities | 38.09M | 29.77M | 26.70M | -- | |
|
|
|||||
| Common Stock & APIC | 764.43M | 45.23M | 44.35M | -- | |
| Retained Earnings | -317.77M | -273.01M | -244.58M | -- | |
| Treasury Stock & Other | 36.00K | 51.00K | 191.00K | -- | |
| Total Common Equity | 446.70M | -227.73M | -200.03M | -- | |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | |
| Preferred Stock Convertible | -- | 349.22M | 323.17M | -- | |
| Preferred Stock, Others | -- | -- | -- | -- | |
| Total Preferred Equity | -- | 349.22M | 323.17M | -- | |
|
|
|||||
| Total Common Equity | 446.70M | -227.73M | -200.03M | -- | |
| Total Preferred Equity | -- | 349.22M | 323.17M | -- | |
| Total Minority Interest | -- | -- | -- | -- | |
| Total Equity | 446.70M | 121.49M | 123.14M | -- | |
|
|
|||||